Literature DB >> 30958738

Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.

Ashwin S Balakrishnan1, Janet E Cowan1, Matthew R Cooperberg1, Katsuto Shinohara1, Hao G Nguyen1, Peter R Carroll1.   

Abstract

PURPOSE: As enrollment in active surveillance expands, it is increasingly important to assess the potential risks of deferred treatment. We evaluated the risk of prostate specific antigen recurrence in a large cohort of men who underwent radical prostatectomy after initial active surveillance.
MATERIALS AND METHODS: The study included men who underwent radical prostatectomy after a period of active surveillance. At diagnosis the men had GG (Gleason Grade Group) 1 or 2, clinical T2 or less and low or intermediate risk disease. They were stratified by a composite variable of GG and the volume of high grade cores at diagnosis. Pathological characteristics and recurrence after radical prostatectomy were evaluated.
RESULTS: Of 1,916 men enrolled in active surveillance between 1994 and 2017, 448 (23.4%) underwent deferred radical prostatectomy. Median time to radical prostatectomy was 27 months (IQR 15.5-46.5). At diagnosis 388 men (86.6%) had GG1 disease, 31 (6.9%) had GG2 disease with 1 high grade core and 29 (6.5%) had GG2 disease with 2 or more high grade cores. GG2 with 2 or more high grade cores at diagnosis was associated with an increased risk of recurrence compared to GG1 disease (HR 3.29, 95% CI 1.49-7.26, p <0.01). GG2 disease with 1 high grade core did not significantly differ from GG1.
CONCLUSIONS: Our results support the careful use of active surveillance in men with GG2 and 1 high grade core at diagnosis. Men with 2 or more high grade (GG2 or greater) cores at diagnosis may benefit from immediate treatment.

Entities:  

Keywords:  local; neoplasm recurrence; prostatectomy; prostatic neoplasms; risk; watchful waiting

Mesh:

Substances:

Year:  2019        PMID: 30958738     DOI: 10.1097/JU.0000000000000247

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Active surveillance before radiotherapy: Outcome and predictive factors for multiple biopsies before treatment.

Authors:  Alexandre Alcaidinho; Guila Delouya; Jean-Paul Bahary; Fred Saad; Daniel Taussky
Journal:  Can Urol Assoc J       Date:  2021-01       Impact factor: 1.862

2.  Deferred radical prostatectomy in patients who initially elected for active surveillance: a multi-institutional, prospective, observational cohort of the PRIAS-JAPAN study.

Authors:  Yoichiro Tohi; Takuma Kato; Masaki Nakamura; Ryuji Matsumoto; Hiroshi Sasaki; Koji Mitsuzuka; Junichi Inokuchi; Katsuyoshi Hashine; Akira Yokomizo; Hirohito Naito; Isao Hara; Norihiko Kawamura; Masaharu Inoue; Hiroshi Fukuhara; Satoru Maruyama; Shinichi Sakamoto; Toshihiro Saito; Shin Egawa; Yoshiyuki Kakehi; Mikio Sugimoto
Journal:  Int J Clin Oncol       Date:  2021-10-02       Impact factor: 3.402

3.  Association Between a 22-feature Genomic Classifier and Biopsy Gleason Upgrade During Active Surveillance for Prostate Cancer.

Authors:  Benjamin H Press; Tashzna Jones; Olamide Olawoyin; Soum D Lokeshwar; Syed N Rahman; Ghazal Khajir; Daniel W Lin; Matthew R Cooperberg; Stacy Loeb; Burcu F Darst; Yingye Zheng; Ronald C Chen; John S Witte; Tyler M Seibert; William J Catalona; Michael S Leapman; Preston C Sprenkle
Journal:  Eur Urol Open Sci       Date:  2022-02-11

Review 4.  Active surveillance for prostate cancer.

Authors:  Daniela K Shill; Monique J Roobol; Behfar Ehdaie; Andrew J Vickers; Sigrid V Carlsson
Journal:  Transl Androl Urol       Date:  2021-06

5.  Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review.

Authors:  Ekaterina Laukhtina; Reza Sari Motlagh; Keiichiro Mori; Fahad Quhal; Victor M Schuettfort; Hadi Mostafaei; Satoshi Katayama; Nico C Grossmann; Guillaume Ploussard; Pierre I Karakiewicz; Alberto Briganti; Mohammad Abufaraj; Dmitry Enikeev; Benjamin Pradere; Shahrokh F Shariat
Journal:  World J Urol       Date:  2021-05-28       Impact factor: 4.226

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.